Morning Consult Health: Senate HELP Markup on PBMs Stalls as Cassidy Blasts Sanders for Changes




 


Health

Essential health care industry news & intel to start your day.
May 3, 2023
Twitter Email
 

Majority of U.S. Adults Support Multiple Public Health Strategies to Address Opioid Epidemic

As drug overdose deaths continue at a staggering rate, more than 4 in 5 adults said that they believe the opioid epidemic is a public health emergency in the United States, according to a new Morning Consult survey.

 

Public health officials and experts are working to reverse, or at least slow, the rate of overdose deaths with strategies aimed at both treating people for addiction and making it safer for people who still use drugs. A majority of U.S. adults supported multiple measures to address the epidemic, including expanding access to rehabilitative services and supplies to use drugs safely, like fentanyl test strips and the overdose medication naloxone.

 

One measure experts advocated for did not have majority support: designated sites for people to safely use drugs.

 

Read the article for more insights, and check back tomorrow for the final part of the series: The Public Supports Most Opioid Harm Reduction Strategies as Experts Push for Better Treatment Options

 

Today’s Top News

  • After what appeared to be bipartisan cooperation to increase oversight of pharmacy benefit managers, the Senate Health, Education, Labor and Pensions Committee’s hearing yesterday to markup the legislation was abruptly adjourned due to partisan infighting. Ranking Republican Bill Cassidy (La.) criticized Chair Bernie Sanders (I-Vt.) for accepting last-minute changes to a group of bills the two had agreed on and for not sharing feedback on the package from the Food and Drug Administration and congressional budget experts. (Stat News)
  • Eli Lilly & Co.’s experimental Alzheimer’s treatment donanemab slowed memory decline by 35% and reduced the likelihood of disease progression by 39% for people who received the antibody infusion, according to clinical trial data from an 18-month study. However, three patients who participated in the study died from brain swelling and bleeding, known side effects of the treatment. (CNBC)
  • CVS Health Corp.’s first-quarter sales increased 11% year over year as growth in the company’s pharmacy and consumer wellness business offset a decline in COVID-19 vaccine and test sales, while net profit for the quarter was $2.14 billion, compared with $2.36 billion in the year-ago period. (The Wall Street Journal) Pfizer Inc.’s first-quarter sales declined 29% year over year to $18.28 billion and net income fell to $5.54 billion, compared to $7.86 billion in the year-ago period, as demand for the company’s COVID-19 vaccine continues to wane. (CNBC)
  • More than 250 Democratic lawmakers signed an amicus brief asking the U.S. 5th Circuit Court of Appeals to reverse its decision to limit access to the abortion drug mifepristone. (The Hill) Meanwhile, a Utah judge temporarily blocked a state law that would have banned abortion clinics if it took effect today, as courts review a lawsuit from the Planned Parenthood Association of Utah and ACLU of Utah. (Axios)

Worth watching today:

  • Senate Finance Committee hearing: “Barriers to Mental Health Care: Improving Provider Directory Accuracy to Reduce the Prevalence of Ghost Networks.” Jack Resneck Jr., president of the American Medical Association, is scheduled to testify.
  • Stat News’ 2023 Breakthrough Summit begins. Speakers include Teladoc Health Inc. Chief Medical Officer Vidya Raman-Tangella and Nkarta Inc. CEO Paul Hastings.
 

Chart Review



 
 

What Else You Need to Know

Coronavirus
 

CDC opens probe after 35 test positive for covid following CDC conference

Lena H. Sun and Dan Diamond, The Washington Post

Attendees say many people did not mask, socially distance or take other precautions recommended earlier in the pandemic.

 

Nursing Homes Brace for End of Pandemic Waivers as Covid Wanes

Tony Pugh, Bloomberg Law

Nursing homes face an uncertain return to normal this month when the federal government reinstates most of the industry regulations that were either waived or relaxed during the Covid-19 pandemic.

 
General
 

New report details the deadly rise of fentanyl in the US

Deidre McPhillips, CNN

Nearly 70,000 people in the US died of drug overdoses that involved fentanyl in 2021, almost a four-fold increase over five years. By 2021, about two-thirds of all overdose deaths involved the potent synthetic opioid, according to the report.

 

Covid-19 inflamed the opioid crisis, particularly for Black Americans

Krista Mahr, Politico

A new CDC report shows that more Black Americans died from fentanyl overdoses than from any other drug in 2021 and at far higher rates than whites or Hispanics.

 

Senator to pitch nearly $1 billion plan to fight fentanyl trafficking

Suzanne Monyak, Roll Call

Roughly half of the funding would aim to expand the ability of border officers to inspect more passenger vehicles entering the country via the U.S.-Mexico border and to improve officers’ ability to seize profits from drug sales leaving the U.S., according to a six-page proposal provided by Murphy’s office.

 

Biden’s pick to lead NIH stares down an increasingly political litany of questions

Sarah Owermohle, Stat News

President Biden’s presumed pick to lead the National Institutes of Health, Monica Bertagnolli, will face a slew of questions on the multibillion-dollar agency’s spending and oversight in her upcoming confirmation battle.

 

Better Flu Shots Have Evaded Us. That Could Soon Change.

Angelica Peebles, Bloomberg

Pfizer Inc., Moderna Inc. and other companies are using the mRNA technology behind the Covid-19 vaccines to improve the flu shot. Though as that work has progressed, it’s become apparent the task is far more challenging and urgent than expected.

 

One Dose of HPV Vaccine Prevents Infection for at Least Three Years

Apoorva Mandavilli, The New York Times

Protection may last even longer, scientists reported. The finding may be a boon to low-income countries, where cervical cancer takes an enormous toll.

 

Why tuberculosis cases have risen in recent years after decades of decline

Aria Bendix, NBC News

After declining for nearly three decades, tuberculosis cases in the U.S. ticked up each year from 2020 to 2022. Cases rose more than 15% in that time, though the disease is still less prevalent than it was before the pandemic.

 

Breast density changes over time could be linked to breast cancer risk, study finds

Jacqueline Howard, CNN

Researchers have long known that women with dense breasts have a higher risk of breast cancer. But according to the study, published last week in the journal JAMA Oncology, the rate of breast density changes over time also appears to be associated with the risk of cancer being diagnosed in that breast.

 

Generic Abortion Pill Maker’s Lawsuit Allowed to Proceed

Celine Castronuovo, Bloomberg Law

Judge Robert C. Chambers of the US District Court for the Southern District of West Virginia denied motions to toss out the case over arguments of lack of standing filed by the state’s attorney general and Putnam County’s prosecuting attorney.

 

Because of Florida abortion laws, she carried her baby to term knowing he would die

Elizabeth Cohen et al., CNN

Florida law allows abortions after 15 weeks if two doctors confirm the diagnosis of a fatal fetal abnormality in writing, but doctors in Florida and states with similar laws have been hesitant to terminate such pregnancies for fear someone will question whether the abnormality was truly fatal.

 

A Vaccine for Birth Control?

Katherine J. Wu, The Atlantic

In its ideal form, a contraceptive vaccine could prevent pregnancy without the messy side effects of some hormonal birth control.

 

What You Need to Know About Stillbirths

Adriana Gallardo and Duaa Eldeib, ProPublica

We spoke to dozens of parents and medical experts about what causes stillbirths, whether there are warning signs to look for during pregnancy, and what your options are if you experience a stillbirth.

 

Federal Rules Don’t Require Period Product Ingredients on Packaging Labels. States Are Stepping In.

Erica Zurek  KFF Health News

New York and California have passed laws requiring disclosure of ingredients on menstrual product packaging. Advocates want more transparency across the U.S.

 

Wisconsin legislators approve opioid settlement payout

The Associated Press

A coalition of states and local governments secured settlements in November and December with opioid manufacturers Teva and Allergan as well as with pharmaceutical chains Walmart, Walgreens and CVS totaling $19.2 billion.

 

NY governor signs bill expanding access to contraceptives

Maysoon Kahn, The Associated Press

Under the law that will take effect in November 2024, trained pharmacists will be able to distribute self-administered hormonal contraceptives including oral birth control pills, vaginal rings, and the patch to New Yorkers, even if patients don’t have a prescription from their doctor or nurse practitioner.

 

North Carolina Republicans reach agreement on 12-week abortion ban

Sharon Bernstein, Reuters

Republican lawmakers in North Carolina said on Tuesday they had reached agreement on a plan to limit most abortions to the first trimester of pregnancy, a sharp drop from the state’s current limit of 20 weeks gestation.

 
Payers
 

Patients Lose Access to Free Medicines Amid Spat Between Drugmakers, Health Plans

Peter Loftus and Joseph Walker, The Wall Street Journal

Johnson & Johnson, Pfizer and other pharmaceutical companies are scaling back programs that cover the copayments of patients or provide free drugs. The programs have been costing drugmakers billions of dollars a year and have been increasing as health plans seeking to control their own spending have tried to take advantage of the assistance.

 

Medicaid formularies cover extended-release buprenorphine more than others, study finds

Anastassia Gliadkovskaya, Fierce Healthcare

The study, published in the latest issue of Health Affairs, examined Medicaid, Medicare Advantage and commercial payer formulary files. It aimed to track insurance-imposed utilization restrictions and other requirements for covering the medication for opioid use disorder from 2017 to 2021.

 

Employer Health Costs to Jump as Medical Inflation Heats Up

Sara Hansard, Bloomberg Law

Employer health-care costs and premiums are likely to climb faster than inflation in 2023 and 2024, according to a survey of health plans covering more than 100 million participants.

 

Arbitration panel hands Envision a victory over UnitedHealth, awards $91.3M judgment

Paige Minemyer, Fierce Healthcare

The independent, three-member panel from the American Arbitration Association made the ruling March 30, Envision said. The arbitrators will also weigh whether Envision is entitled to attorney’s fees as well as prejudgment interest, according to the news release.

 
Providers
 

Leapfrog Group safety grades reflect hospital struggles amid pandemic peaks

Mari Devereaux, Modern Healthcare

The organization’s new data on hospital safety performance shows increases in infection ratios during the 2021-2022 period compared with pre-pandemic levels.

 

North Carolina bill would carve UNC hospitals out of antitrust laws

Maya Goldman, Axios

The bill could increase health care consolidation in the state by making it easier for the University of North Carolina-affiliated hospital system to acquire other health care organizations.

 

Hospitals’ 340B participation tied to reduced biosimilar uptake, study finds

Dave Muoio, Fierce Healthcare

Hospitals’ participation in the 340B Drug Pricing Program appears to be associated with increased overall use of biologic medications but reduced adoption of lower-cost biosimilar drugs, a trend researchers described as a potential “distortion of incentives” that could warrant reform.

 

How malpractice insurers are navigating abortion bans

Kara Hartnett, Modern Healthcare

In states with narrow exceptions to abortion bans, doctors must determine how near a patient is to death to lawfully warrant the procedure. Delaying intervention can result in negative health outcomes that may prompt patients to file malpractice lawsuits. But offering abortion care more quickly could trigger criminal charges.

 

After Idaho’s Strict Abortion Ban, OB-GYNs Stage a Quick Exodus

Sarah Varney, KFF Health News

At least two Idaho hospitals are ending labor and delivery services, with one citing the state’s “legal and political climate” and noting that “recruiting replacements will be extraordinarily difficult” as doctors leave.

 
Pharma, Biotech and Devices
 

J&J, building on CAR-T success, strikes another cell therapy deal

Delilah Alvarado, BioPharma Dive

The deal, announced Tuesday with the Maryland-based Cellular Biomedicine Group, has J&J paying $245 million upfront to gain access to two CAR-T therapies that have shown positive early-phase results in patients with recurrent diffuse large B cell lymphoma, or DLBCL, the most common form of non-Hodgkin lymphoma.

 

Amgen sues Novartis to block generic osteoporosis, bone cancer drugs

Blake Brittain, Reuters

Amgen Inc sued Novartis AG’s Sandoz in New Jersey federal court Monday, accusing Sandoz’s proposed versions of its multibillion-dollar bone-strengthening drugs Prolia and Xgeva of infringing several patents.

 

PhRMA renews pharmacy benefits manager campaign as Congressional scrutiny heats up

Beth Snyder Bulik, Endpoints News

The ad is the third in PhRMA’s campaign series highlighting the role of PBMs, with the latest coming as the Senate health committee led by Sens. Bernie Sanders (I-VT) and Bill Cassidy (R-LA) prepares to work on new drug pricing legislation that includes increasing oversight and transparency around PBMs.

 

Gene therapy for muscular dystrophy stirs hopes and controversy

Rob Stein, NPR News

The FDA is considering greenlighting the experimental treatment under its accelerated approvals program. Some critics point out the therapy isn’t yet proven to work and may be costly.

 

From science to strategy, this exec is painting Genmab’s bigger picture into the next decade

Michael Gibney, PharmaVoice

Martine van Vugt, recently named Genmab’s chief strategy officer and executive vice president, aims to usher in the company’s next wave of “knock your socks off” antibodies.

 
Health Technology
 

Masimo suit against Apple over smartwatch trade secrets ends in mistrial

Susan Kelly, MedTech Dive

The medical device maker said it intends to retry the lawsuit, as it awaits a decision from the International Trade Commission on a separate investigation into patent infringement claims against Apple.

 

Talkspace enterprise business soars, DTC falters

Gabriel Perna, Modern Healthcare

The digital therapy company saw business-to-business revenue grow 70% to $23.4 million in the first quarter. Talkspace reported 171.7 million completed sessions through enterprise customers, which include health insurance companies and employers, a 90% increase. 

 

Why Boston Children’s wants to hire a ChatGPT expert

Gabriel Perna, Digital Health Business & Technology

Dr. John Brownstein, chief innovation officer at Boston Children’s, said it didn’t take him long to realize the technology’s potential. “Right out of the box, I don’t think I’ve seen anything as transformational since the iPhone or Google,” he said.

 

Merck entitled to $1.4B in cyberattack case after court rejects insurers’ ‘warlike action’ claim

Angus Liu, Fierce Pharma

A New Jersey appellate court on Monday ruled that a group of insurers can’t use war as an argument to deny Merck coverage from the notorious cyberattack that afflicted the company and others back in 2017.

 







Morning Consult